- Q1 FY2026 net sales rose 40% year-over-year to $363.9 million, driven by strong Animal Health growth.
- Adjusted EBITDA increased 101% to $61.9 million; adjusted diluted EPS doubled to $0.73.
- Animal Health revenue up 55%, led by MFAs, nutritional specialties, and vaccines.
- Phibro raised FY2026 Adjusted EBITDA guidance to $230–$240 million while maintaining sales guidance of $1.43–$1.48 billion.
- Launch of Restoris™, a dental gel for dogs, marks entry into companion animal oral health segment.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported first-quarter fiscal 2026 results, delivering a 40% increase in net sales to $363.9 million and a 101% jump in adjusted EBITDA to $61.9 million compared with the prior year. Net income rose to $26.5 million, with adjusted diluted earnings per share doubling to $0.73. The company also raised its fiscal 2026 earnings outlook following strong operational performance in its Animal Health segment.
“Phibro delivered an outstanding start to fiscal 2026, with net sales up 40% and earnings growth driven by robust demand for MFAs, nutritional specialties, and vaccines,” said Jack Bendheim, President and Chief Executive Officer. “Our strong execution and the success of our Phibro Forward initiatives are allowing us to invest strategically in innovation across animal health.”
Animal Health sales climbed 55% to $283.5 million, led by increased demand across North and South America and contributions from the acquired Zoetis Medicated Feed Additive portfolio. Nutritional specialties grew 13% and vaccines advanced 25% globally, with particular strength in poultry markets. Mineral Nutrition increased 7% to $63 million, while Performance Products declined 7% due to lower personal care ingredient demand.
Gross profit rose 43% to $119.8 million, reflecting higher sales volumes and improved product mix. Adjusted net income was $29.8 million, up 113% year-over-year. The company maintained a healthy balance sheet with $85.3 million in cash and short-term investments and a 3.3x gross leverage ratio.
Phibro’s updated fiscal 2026 guidance projects net sales of $1.43–$1.48 billion (12% growth) and adjusted EBITDA of $230–$240 million (28% growth). Adjusted diluted EPS is forecast at $2.64–$2.81, representing 31% growth year-over-year. The company continues to expect an adjusted effective tax rate of approximately 25%.
Phibro also highlighted progress in its companion animal business, including the national launch of Restoris™, a breakthrough dental gel for dogs with periodontal disease, and the development of a new therapeutic compound for canine oral care.
Information sourced from the company’s press release.
